Particle Embolization of Hepatic Neuroendocrine Metastases for Control of Pain and Hormonal Symptoms

Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Journal of Vascular and Interventional Radiology (Impact Factor: 2.41). 05/1999; 10(4):397-403. DOI: 10.1016/S1051-0443(99)70055-2
Source: PubMed


To evaluate treatment outcome with respect to the indication for treatment in patients with neuroendocrine tumors metastatic to the liver undergoing hepatic artery embolization with polyvinyl alcohol (PVA) particles.
Charts and radiographs were reviewed of 35 patients undergoing 63 separate sessions of embolotherapy between January 1993 and July 1997. Patient demographics, tumor type, indication for embolization, and complications were recorded. Symptomatic and morphologic responses to therapy were noted, as well as duration of response.
Fourteen men and 21 women underwent embolization of 21 carcinoid and 14 islet cell tumors metastatic to the liver. These patients underwent 63 separate episodes of embolotherapy. Of 48 episodes that could be evaluated, response to treatment was noted following 46 episodes (96%). The duration of response was longest in patients treated for hormonal symptoms with (17.5 months) or without (16 months) pain, and was shortest (6.2 months) when the indication was pain alone. Complications occurred after 11 of the 63 embolizations (17%), including four (6%) deaths. Cumulative 5-year survival following embolotherapy was 54%.
Hepatic artery embolization with PVA particles is beneficial for patients with neuroendocrine tumors metastatic to the liver and may be used for control of pain as well as hormonal symptoms. This therapy should be used cautiously when more than 75% of the hepatic parenchyma is replaced by tumor.

8 Reads
  • Source
    • "TAE appears to be an optimal treatment approach for inoperable liver metastases from NENs, for higher metastatic load, for management of symptoms alone and in association with interferon or somatostatin analogues, suggesting a prolonged 5-yr survival and local tumor control and for survival improvement [42,43,45,51]. Tumor response as well as survival, but not clinical and biochemical response, appear to be better for patients with carcinoid than pancreatic NENs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver metastases occur in 46-93% of patients with neuroendocrine neoplasms (NENs). Presence and extension of liver metastases are considered important prognostic factors, as they may significantly impair the patient’s quality of life, because of either tumor bulk or hormonal hypersecretion. Therapies for NEN liver metastases include surgical resection, liver transplantation, chemotherapy and biotherapy. Surgery is the gold standard for curative therapy, but in most of NEN patients with liver metastases, when surgery can not be applied, minimally invasive therapeutic approaches are adopted. They include trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), radiofrequency thermal ablation and new emerging techniques. TAE is based on selective infusion of particles in the branch of the hepatic artery supplying the tumor lesions. The goal of TAE is to occlude tumor blood vessels resulting in ischemia and necrosis. Many reports have shown that TAE can reduce tumor size and hormone output, resulting in palliation of symptoms without the use of cytotoxic drugs, resulting in better tolerability. This review will focus on TAE performance and safety in NEN patients with liver metastases.
    Journal of Experimental & Clinical Cancer Research 05/2014; 33(1):43. DOI:10.1186/1756-9966-33-43 · 4.43 Impact Factor
  • Source
    • "Hepatic failure, hepatic abscess, hepatorenal syndrome, sepsis, and severe hypertension occurring during embolization can all result from the local ischemia induced by arterial embolization [11, 13, 16, 30, 31, 33, 36]. Patients with bilioenteric anastomoses or large tumors (greater than 5 cm) are especially at risk for hepatic abscess formation after embolization [47, 48]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroendocrine tumors (NETs) have a high predilection for metastasizing to the liver and can cause severe debilitating symptoms adversely affecting quality of life. Although surgery remains the treatment of choice, many liver metastases are inoperable at presentation. Hepatic arterial embolization procedures take advantage of the arterial supply of NET metastases. The goals of these therapies are twofold: to increase overall survival by stabilizing tumor growth, and to reduce the morbidity in symptomatic patients. Patients treated with hepatic arterial embolization demonstrate longer progression-free survival and have 5-year survival rates of nearly 30%. The safety of repeat embolizations has also been proven in the setting of recurrent symptoms or progression of the disease. Despite not being curative, hepatic arterial embolization should be used in the management of NETs with liver metastases. Long-term survival is not uncommon, making aggressive palliation of symptoms an important component of treatment.
    01/2012; 2012(1):471203. DOI:10.1155/2012/471203
  • Source
    • "Embolization of the hepatic arterial blood supply can be performed with or without the concurrent injection of chemotherapy. The response rates associated with embolization , as measured either by decrease in hormonal secretion or by radiographic regression, are generally greater than 50% [99] [100] [101] [102] [103] [104] [105] [106] [107] [108]. The duration of response can be brief, however, ranging from 4 to 24 months in uncontrolled series [100] [103]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The generally indolent nature of neuroendocrine tumors is an advantage in the management of patients who have localized disease, and surgery alone is often curative. This same property presents a challenge in the treatment of patients who have metastatic disease, in whom standard cytotoxic chemotherapy has a limited benefit. In such patients, the use of somatostatin analogs, interferon, and the treatment of hepatic metastases may provide effective palliation. The highly vascular nature of carcinoid tumors has led to the investigation of antiangiogenic agents in this setting. Preliminary reports of activity associated with agents targeting the vascular endothelial growth factor pathway suggest that such strategies may play a role in the future treatment of patients who have this disease.
    Hematology/Oncology Clinics of North America 07/2007; 21(3):433-55; vii-viii. DOI:10.1016/j.hoc.2007.04.004 · 2.30 Impact Factor
Show more